Calling all men with hemophilia B, aged 18 years or older, treated with Rebinyn

ICON Plc, a patient-centred research company, is conducting a new research study to better understand the day-to-day experiences and quality of life of men with hemophilia B, treated with Rebinyn, and how their treatment impacts them. ICON has been engaged by the study sponsor, Novo Nordisk, a pharmaceutical company, to conduct these interviews.

This study consists of a one-hour phone interview with an experienced moderator from ICON. All information provided by participants will be confidential and names or any identifying information will not be included in the results.

The study is open to men with hemophilia B, aged 18 years or older, and specifically taking the medication Rebinyn for at least three months. ICON hopes to recruit around 20 people to the study to ensure they have a good understanding of the range of benefits and issues faced by patients.

Any personal information provided during the interview will not be shared unless the participant provides consent to share his information specifically to report any safety issues. However, de-identified (all identifying information removed) and aggregated results of the study may be used in scientific communications.

To sign up or to find out more, please contact Jeremy Lambert at Jeremy.lambert@iconplc.com.

For residents in the Newfoundland and Labrador province, if you have any questions regarding your rights as a research participant, you may contact the Office of the Health Research Ethics Board (HREB) at 709-777-6974 or e-mail at info@hrea.ca.